BioSight
Companies
Janux Therapeutics, Inc. logo

JANX

NASDAQSAN DIEGO, CA
Janux Therapeutics, Inc.

Janux Therapeutics develops immunotherapy product candidates using three proprietary platform technologies: TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator). The company is in the research and development stage, conducting preclinical studies and clinical trials across multiple cancer indications. Janux aims to eventually obtain regulatory approval and commercialize these product candidates, though it currently depends on external funding to support its operations.

Price history not yet available for JANX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar